Skip to main content

Oligodendroglioma

  • Chapter
  • First Online:
Brain Tumors
  • 261 Accesses

Abstract

Oligodendrogliomas and Anaplastic Oligodendrogliomas are the slowest-growing and the most treatment sensitive of gliomas in adults. While these tumors have specific histologic characteristics, they are molecularly defined by the IDH mutation and the 1p/19q co-deletion. Few prospective have been done specifically in oligodendrogliomas and some treatment strategies are extrapolated from clinical studies that included astrocytomas. Treatment today is define by maximal safe surgical resection followed by radiation and chemotherapy. Due to the chemosensitivity of these tumors, there may be safe approaches to defer radiotherapy. In this chapter, we discuss the evidence that guides decision-making for clinicians. Prognosis for these tumors is measured in years and decades.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Subscribe and save

Springer+ Basic
EUR 32.99 /Month
  • Get 10 units per month
  • Download Article/Chapter or Ebook
  • 1 Unit = 1 Article or 1 Chapter
  • Cancel anytime
Subscribe now

Buy Now

eBook
USD 24.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 32.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Similar content being viewed by others

References

  1. Louis DN, et al. The 2021 WHO classification of tumors of the central nervous system: a summary. Neuro Oncol. 2021;23(8):1231–51.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  2. Morshed RA, et al. Molecular features and clinical outcomes in surgically treated low-grade diffuse gliomas in patients over the age of 60. J Neurooncol. 2019;141(2):383–91.

    Article  CAS  PubMed  Google Scholar 

  3. Pinkham MB, et al. FISHing tips: what every clinician should know about 1p19q analysis in gliomas using fluorescence in situ hybridisation. Clin Oncol (R Coll Radiol). 2015;27(8):445–53.

    Article  CAS  PubMed  Google Scholar 

  4. Appay R, et al. CDKN2A homozygous deletion is a strong adverse prognosis factor in diffuse malignant IDH-mutant gliomas. Neuro Oncol. 2019;21(12):1519–28.

    CAS  PubMed  PubMed Central  Google Scholar 

  5. Press RH, et al. Optimal timing of chemoradiotherapy after surgical resection of glioblastoma: stratification by validated prognostic classification. Cancer. 2020;126(14):3255–64.

    Article  PubMed  Google Scholar 

  6. Mohile NA, et al. Therapy for diffuse astrocytic and oligodendroglial tumors in adults: ASCO-SNO guideline. J Clin Oncol. 2022;40(4):403–26.

    Article  CAS  PubMed  Google Scholar 

  7. Weller M, et al. EANO guidelines on the diagnosis and treatment of diffuse gliomas of adulthood. Nat Rev Clin Oncol. 2021;18(3):170–86.

    Article  PubMed  Google Scholar 

  8. Shaw EG, et al. Randomized trial of radiation therapy plus procarbazine, lomustine, and vincristine chemotherapy for supratentorial adult low-grade glioma: initial results of RTOG 9802. J Clin Oncol. 2012;30(25):3065–70.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  9. van den Bent MJ, et al. Adjuvant procarbazine, lomustine, and vincristine chemotherapy in newly diagnosed anaplastic oligodendroglioma: long-term follow-up of EORTC brain tumor group study 26951. J Clin Oncol. 2013;31(3):344–50.

    Article  PubMed  Google Scholar 

  10. Niyazi M, et al. ESTRO-ACROP guideline “target delineation of glioblastomas”. Radiother Oncol. 2016;118(1):35–42.

    Article  PubMed  Google Scholar 

  11. Cairncross G, et al. Phase III trial of chemoradiotherapy for anaplastic oligodendroglioma: long-term results of RTOG 9402. J Clin Oncol. 2013;31(3):337–43.

    Article  CAS  PubMed  Google Scholar 

  12. Nabors LB, et al. NCCN guidelines insights: central nervous system cancers, version 1.2017. J Natl Compr Cancer Netw. 2017;15(11):1331–45.

    Article  Google Scholar 

  13. Miller JJ. Targeting IDH-mutant glioma. Neurotherapeutics. 2022;19:1724–32.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  14. Olson JD, Riedel E, DeAngelis LM. Long-term outcome of low-grade oligodendroglioma and mixed glioma. Neurology. 2000;54(7):1442–8.

    Article  CAS  PubMed  Google Scholar 

  15. Iwadate Y, et al. Eighty percent survival rate at 15 years for 1p/19q co-deleted oligodendroglioma treated with upfront chemotherapy irrespective of tumor grade. J Neurooncol. 2019;141(1):205–11.

    Article  CAS  PubMed  Google Scholar 

  16. Ostrom QT, et al. CBTRUS statistical report: primary brain and other central nervous system tumors diagnosed in the United States in 2010-2014. Neuro Oncol. 2017;19(suppl_5):v1–v88.

    Article  PubMed  PubMed Central  Google Scholar 

  17. Kerkhof M, et al. Seizures in oligodendroglial tumors. CNS Oncol. 2015;4(5):347–56.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  18. Jaeckle KA, et al. CODEL: phase III study of RT, RT + TMZ, or TMZ for newly diagnosed 1p/19q codeleted oligodendroglioma. Analysis from the initial study design. Neuro Oncol. 2021;23(3):457–67.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Oluwatosin Akintola .

Editor information

Editors and Affiliations

Rights and permissions

Reprints and permissions

Copyright information

© 2023 The Author(s), under exclusive license to Springer Nature Switzerland AG

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Akintola, O. (2023). Oligodendroglioma. In: Mohile, N.A., Thomas, A.A. (eds) Brain Tumors. Springer, Cham. https://doi.org/10.1007/978-3-031-41413-8_3

Download citation

  • DOI: https://doi.org/10.1007/978-3-031-41413-8_3

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-031-41412-1

  • Online ISBN: 978-3-031-41413-8

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics